Patents by Inventor Daniel Robbins
Daniel Robbins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11472816Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.Type: GrantFiled: December 4, 2020Date of Patent: October 18, 2022Assignee: AstraZeneca ABInventors: Alexander Hird, Matthew Belmonte, Wenzhan Yang, Paul Secrist, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
-
Publication number: 20220324835Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.Type: ApplicationFiled: January 25, 2019Publication date: October 13, 2022Inventors: Paul A. BARSANTI, Neil F. BENCE, Jennifa GOSLING, Anjanabha SAHA, Asad M TAHERBHOY, Christoph W. ZAPF, Kathleen BOYLE, Mario CARDOZO, Jeffrey MIHALIC, Morgan LAWRENZ, Mark GALLOP, Jilliane BRUFFEY, Thomas CUMMINS, Daniel ROBBINS, Hiroko TANAKA, Chenbo WANG, Frederick COHEN, Wylie PALMER, Arthur T. SANDS, Hunter SHUNATONA
-
Publication number: 20210230184Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.Type: ApplicationFiled: December 4, 2020Publication date: July 29, 2021Applicant: AstraZeneca ABInventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, XiaoLan ZHENG
-
Patent number: 10889594Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15,016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.Type: GrantFiled: December 18, 2018Date of Patent: January 12, 2021Assignee: AstraZeneca ABInventors: Alexander Hird, Wenzhan Yang, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
-
Patent number: 10459870Abstract: A system includes a medical monitor having a sensor input responsive to a sensor signal representative of a physiological parameter; a processor that may calculate the physiological parameter from the sensor signal; an output port in communication with the processor to output medical data comprising the calculated physiological parameter in a first communication protocol; a removable interface having an input port receptive of the medical data in the first communication protocol; a memory storing code that may translate the medical data into a second communication protocol; and a first output port that may transmit the medical data in the second communication protocol to an external system that recognizes the second communication protocol and not the first communication protocol.Type: GrantFiled: September 6, 2018Date of Patent: October 29, 2019Assignee: COVIDIEN LPInventors: Dev Devanayagom Joshua, Daniel Robbin Letcher, Aaron Damian Macan
-
Publication number: 20190185485Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15,016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.Type: ApplicationFiled: December 18, 2018Publication date: June 20, 2019Inventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, Xiaolan ZHENG
-
Publication number: 20190073333Abstract: A system includes a medical monitor having a sensor input responsive to a sensor signal representative of a physiological parameter; a processor that may calculate the physiological parameter from the sensor signal; an output port in communication with the processor to output medical data comprising the calculated physiological parameter in a first communication protocol; a removable interface having an input port receptive of the medical data in the first communication protocol; a memory storing code that may translate the medical data into a second communication protocol; and a first output port that may transmit the medical data in the second communication protocol to an external system that recognizes the second communication protocol and not the first communication protocol.Type: ApplicationFiled: September 6, 2018Publication date: March 7, 2019Inventors: Dev Devanayagom Joshua, Daniel Robbin Letcher, Aaron Damian Macan
-
Patent number: 10196404Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.Type: GrantFiled: October 23, 2017Date of Patent: February 5, 2019Assignee: AstraZeneca ABInventors: Alexander Hird, Matthew Belmonte, Wenzhan Yang, Paul Secrist, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
-
Patent number: 10095649Abstract: A system includes a medical monitor having a sensor input responsive to a sensor signal representative of a physiological parameter; a processor that may calculate the physiological parameter from the sensor signal; an output port in communication with the processor to output medical data comprising the calculated physiological parameter in a first communication protocol; a removable interface having an input port receptive of the medical data in the first communication protocol; a memory storing code that may translate the medical data into a second communication protocol; and a first output port that may transmit the medical data in the second communication protocol to an external system that recognizes the second communication protocol and not the first communication protocol.Type: GrantFiled: June 29, 2016Date of Patent: October 9, 2018Assignee: Covidien LPInventors: Dev Devanayagom Joshua, Daniel Robbin Letcher, Aaron Damian Macan
-
Patent number: 10022172Abstract: A percutaneous system in which tubular retractors are utilized as a means of access, visualization, and a controlled orientation for preparation of posterior spinal elements and delivery of graft material for posterior spinal fusion. The tubular retractors are affixed to screw extensions to rotate and articulate relative to multi-axial screws percutaneously inserted into respective pedicles of vertebral bodies. The procedure is done bilaterally, although it could be performed unilaterally in cases where the anatomy or surgeon preference dictates. A number of different deployable graft concepts are disclosed, the primary features being to allow for creation of a graft space volume and a means for delivery of the graft material preferred by the surgeon.Type: GrantFiled: June 16, 2015Date of Patent: July 17, 2018Assignee: SPINE WAVE, INC.Inventors: Lawrence M. Boyd, John J. Ratcliffe, Jr., Joshua Morin, Shresta Marigowda, Tim E. Adamson, Daniel Robbins, Thomas J. Barbieri
-
Publication number: 20180155362Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.Type: ApplicationFiled: October 23, 2017Publication date: June 7, 2018Applicant: AstraZeneca ABInventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, Xiaolan ZHENG
-
Patent number: 9840518Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.Type: GrantFiled: April 21, 2017Date of Patent: December 12, 2017Assignee: ASTRAZENECA ABInventors: Alexander Hird, Wenzhan Yang, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb
-
Publication number: 20170337746Abstract: The invention disclosed herein provides systems and methods for simplifying augmented reality or virtual augmented reality based communication collaboration, and decision making through a streamlined user interface framework that enables both synchronous and asynchronous interactions in immersive environments.Type: ApplicationFiled: August 4, 2017Publication date: November 23, 2017Applicant: 30 60 90 CorporationInventors: John SanGiovanni, Sean B. House, Ethan Lincoln, John Adam Szofran, Daniel Robbins, Ana Martha Arellano lopez, Ursala Seelstra, Michelle McMullen
-
Publication number: 20170316611Abstract: The invention disclosed herein provides systems and methods for simplifying augmented reality or virtual augmented reality based communication collaboration, and decision making through a streamlined user interface framework that enables both synchronous and asynchronous interactions in immersive environments.Type: ApplicationFiled: December 31, 2016Publication date: November 2, 2017Inventors: John SanGiovanni, Sean B. House, Ethan Lincoln, Daniel Robbins, Ana Martha Arellano Lopez, Ursula Seelstra, Michelle McMullen, John Adam Szofran
-
Publication number: 20170305926Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.Type: ApplicationFiled: April 21, 2017Publication date: October 26, 2017Applicant: AstraZeneca ABInventors: Alexander HIRD, Wenzhan YANG, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB
-
Publication number: 20170004106Abstract: A system includes a medical monitor having a sensor input responsive to a sensor signal representative of a physiological parameter; a processor that may calculate the physiological parameter from the sensor signal; an output port in communication with the processor to output medical data comprising the calculated physiological parameter in a first communication protocol; a removable interface having an input port receptive of the medical data in the first communication protocol; a memory storing code that may translate the medical data into a second communication protocol; and a first output port that may transmit the medical data in the second communication protocol to an external system that recognizes the second communication protocol and not the first communication protocol.Type: ApplicationFiled: June 29, 2016Publication date: January 5, 2017Inventors: Dev Devanayagom Joshua, Daniel Robbin Letcher, Aaron Damian Macan
-
Patent number: 9328061Abstract: The present invention provides organic molecules and methods thereof for reactions between organoboron reagents and double bonds, such as imines or carbonyls, to stereoselectively provide chiral products including amines and alcohols, entities useful for the preparation of biologically active molecules.Type: GrantFiled: March 1, 2013Date of Patent: May 3, 2016Assignee: Trustees of Boston CollegeInventors: Amir H. Hoveyda, Daniel L. Silverio, Tatiana Pilyugina, Sebastian Torker, Daniel Robbins
-
Publication number: 20150374354Abstract: A percutaneous system in which tubular retractors are utilized as a means of access, visualization, and a controlled orientation for preparation of posterior spinal elements and delivery of graft material for posterior spinal fusion. The tubular retractors are affixed to screw extensions to rotate and articulate relative to multi-axial screws percutaneously inserted into respective pedicles of vertebral bodies. The procedure is done bilaterally, although it could be performed unilaterally in cases where the anatomy or surgeon preference dictates. A number of different deployable graft concepts are disclosed, the primary features being to allow for creation of a graft space volume and a means for delivery of the graft material preferred by the surgeon.Type: ApplicationFiled: June 16, 2015Publication date: December 31, 2015Inventors: LAWRENCE M. BOYD, JOHN J. RATCLIFFE, JR., JOSHUA MORIN, SHRESTA MARIGOWDA, TIM E. ADAMSON, DANIEL ROBBINS, THOMAS J. BARBIERI
-
Publication number: 20150057451Abstract: The present invention provides organic molecules and methods thereof for reactions between organoboron reagents and double bonds, such as imines or carbonyls, to stereoselectively provide chiral products including amines and alcohols, entities useful for the preparation of biologically active molecules.Type: ApplicationFiled: March 1, 2013Publication date: February 26, 2015Inventors: Amir H. Hoveyda, Daniel L. Silverio, Tatiana Pilyugina, Sebastian Torker, Daniel Robbins
-
Patent number: D1019880Type: GrantFiled: March 29, 2022Date of Patent: March 26, 2024Assignee: Access Business Group International LLCInventors: Daniel L. Schlenk, Rebecca C. Musante, Tedmund A. Robbins, Cynthia Andreason, Matthew J. Norconk, Timothy D. Stoepker, Sarah E. Gesink